The application relates to a protein dimer formed by a first and a second fusion protein, wherein the first fusion protein comprises a cystine knot domain (CK) fused to a first pharmaceutically active protein and the second fusion protein comprises a CK domain fused to a second pharmaceutically active protein, wherein the two fusion proteins are covalently linked by their CK domains. The application further relates to the individual fusion proteins, to the polynucleotide encoding the fusion proteins, the vector comprising the polynucleotide and the host cell comprising the vector.
The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
EDP software for the prediction of chemical processes, preferably based on analytical data based on a mathematical forecasting model, in particular for the prediction of diffusion rates between materials of the same and different states of matter, for example for the prediction of extractables and leachables [E&Ls] in pharmaceutical and medical production processes Chemical/pharmaceutical testing relating to the release of harmful substances in the chemical/pharmaceutical industry, in particular relating to extractables and leachables in the manufacture of pharmaceutical products or medicines; Preparation of application-related studies into extractables and leachables, toxicological risk assessment of extractables and leachables, studies in the pharmaceutical sector relating to extractables and leachables; Development of methods and validation of methods for extractables and leachables
4.
BIODEGRADABLE, NON-POROUS MEDICAL DEVICE AND METHODS FOR MAKING AND USING THE SAME
The present invention relates to biodegradable, non-porous medical devices and particular to such devices comprising a sheet-like structural layer and a multi-layered water-activatable adhesive component. The invention further relates to methods of making and using the biodegradable, non-porous medical devices. Embodiments of the invention have been particularly developed for making flexible yet burst-resistant biodegradable, non-porous medical devices, where the devices adhesive component renders them particularly useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/64 - Utilisation de matériaux caractérisés par leur fonction ou leurs propriétés physiques spécialement adaptés pour être résorbables à l'intérieur du corps
A61L 15/26 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carboneLeurs dérivés
A61L 15/32 - Protéines, polypeptidesLeurs produits de dégradation ou leurs dérivés, p. ex. albumine, collagène, fibrine, gélatine
A61L 15/38 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des enzymes
Mold for applying a liquid onto a plasma-based or cryoprecipitate-based film comprising at least one frame (1) configured for carrying said plasma-based or cryoprecipitate-based film, at least one base plate (2) and at least one mold body (3) with at least one passage (10), wherein said frame (1) is arranged between said base plate (2) and said mold body (3) such that said liquid can be applied, preferably poured or sprayed, onto said plasma-based or cryoprecipitate-based film through said passage (10). Further, a method for coating a plasma-based or cryoprecipitate-based film is described.
B05B 13/02 - Moyens pour supporter l'ouvrageDisposition ou assemblage des têtes de pulvérisationAdaptation ou disposition des moyens pour entraîner des pièces
B05B 12/20 - Éléments de masquage, c.-à-d. éléments définissant des aires non revêtues sur un objet à revêtir
B05C 3/18 - Appareillages dans lesquels un ouvrage est mis en contact avec une grande quantité de liquide ou autre matériau fluide un côté uniquement de l'ouvrage venant en contact avec le liquide ou autre matériau fluide
B05C 13/02 - Moyens pour manipuler ou tenir des objets, p. ex. des objets individuels pour des objets particuliers
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
EDP software for the prediction of chemical processes, preferably based on analytical data based on a mathematical forecasting model, in particular for the prediction of diffusion rates between materials of the same and different states of matter, for example for the prediction of extractables and leachables [E&Ls] in pharmaceutical and medical production processes. Chemical/pharmaceutical testing relating to the release of harmful substances in the chemical/pharmaceutical industry, in particular relating to extractables and leachables in the manufacture of pharmaceutical products or medicines; Preparation of application-related studies into extractables and leachables, toxicological risk assessment of extractables and leachables, studies in the pharmaceutical sector relating to extractables and leachables; Development of methods and validation of methods for extractables and leachables.
The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.
The invention relates to a fusion protein comprising: a Factor VIII (FVIII) heavy chain; an FVIII light chain; a fragment of von Willebrand Factor (VWF); and at least two copies of an extension peptide (EP); wherein the EP has at least 90 % amino acid sequence identity to SEQ ID NO: 1 and contains a cluster of O-glycosylation sites, wherein the cluster contains at least two O-glycosylated amino acids. The complex shows improved pharmacokinetic properties in comparison to FVIII. The invention further relates to a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
The present invention relates to human albumin solutions and in particular to methods and uses of preparing them. The invention further relates to human albumin solutions, which have an increased mercaptalbumin content and/or an increased transport capacity for reactive oxygen species, reactive nitrogen species as well as endogenous and exogenous ligands. Embodiments of the invention have been particularly developed for use in the treatment of disease and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes and blood components, especially blood plasma Hosting software platforms and websites on the internet for others, in the field of blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes and blood components, especially blood plasma Hosting software platforms and websites on the internet for others, in the field of blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes and blood components, especially blood plasma Hosting software platforms and websites on the internet for others, in the field of blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.
The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.
The present invention relates to biodegradable, non-porous medical devices and particular to such devices comprising a sheet-like structural layer and a multi- layered water-activatable adhesive component. The invention further relates to methods of making and using the biodegradable, non-porous medical devices. Embodiments of the invention have been particularly developed for making flexible yet burst-resistant biodegradable, non-porous medical devices, where the devices adhesive component renders them particularly useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/26 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carboneLeurs dérivés
A61L 15/38 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des enzymes
A61L 15/42 - Utilisation de matériaux caractérisés par leur fonction ou leurs propriétés physiques
A61L 15/40 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des ingrédients de constitution indéterminée ou leurs produits de réaction
A61L 31/00 - Matériaux pour autres articles chirurgicaux
Mold for applying a liquid onto a plasma-based or cryoprecipitate-based film comprising at least one frame (1) configured for carrying said plasma-based or cryoprecipitate-based film, at least one base plate (2) and at least one mold body (3) with at least one passage (10), wherein said frame (1) is arranged between said base plate (2) and said mold body (3) such that said liquid can be applied, preferably poured or sprayed, onto said plasma-based or cryoprecipitate-based film through said passage (10). Further, a method for coating a plasma-based or cryoprecipitate-based film is described.
B05C 13/02 - Moyens pour manipuler ou tenir des objets, p. ex. des objets individuels pour des objets particuliers
B05B 12/20 - Éléments de masquage, c.-à-d. éléments définissant des aires non revêtues sur un objet à revêtir
B05B 13/02 - Moyens pour supporter l'ouvrageDisposition ou assemblage des têtes de pulvérisationAdaptation ou disposition des moyens pour entraîner des pièces
B05B 15/80 - Aménagements dans lesquels l’aire de pulvérisation n’est pas confinée, p. ex. tables de pulvérisation
B05C 3/18 - Appareillages dans lesquels un ouvrage est mis en contact avec une grande quantité de liquide ou autre matériau fluide un côté uniquement de l'ouvrage venant en contact avec le liquide ou autre matériau fluide
The invention relates to a pharmaceutical composition comprising an isolated Factor VIII protein and/or an isolated VWF protein in a stabilizing buffer composition, wherein said pharmaceutical composition is free of albumin and said stabilizing buffer 5 composition comprises cryoprotectants and bulking agents in a weight ratio of more than 0.65:1. The invention relates further relates to the use of a stabilizing buffer formulating an FVIII protein and/or a VWF protein to the use of a VWF protein for stabilizing a FVIII protein in vitro.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation, as well as patient support information and patient support programs Blood bank services, blood donation being blood bank services; providing health information relating to blood products and blood donation; providing patient support information being heath information Patient support programs being personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation, as well as patient support information and patient support programs Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation; providing patient support information being health information Patient support programs being personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood products and blood donation
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Blood for medical purposes, blood components, namely, blood plasma, platelet-rich blood plasma, stem cells for medical use, bone marrow concentrate and platelets for medical use Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation
39.
STORAGE STABLE FILMS COMPRISING FIBRIN AND/OR FIBRINOGEN
Described herein are dried films comprising fibrin and/or fibrinogen, and methods of using same. In certain aspects, the dried films are storage stable at room temperature. In certain aspects, the dried films described herein are effective for preventing or treating a wound in a subject in need thereof.
Advertising and business services, namely, business consulting, business administration, business operational advisory services, business marketing services, business information services, business management consulting services, business administrative services for medical and pharmaceutical referrals
41.
FX activation process and its use in the preparation of a FXa composition
The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
45.
Plasma-based films and methods for making and using the same
The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/40 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des ingrédients de constitution indéterminée ou leurs produits de réaction
A61L 31/00 - Matériaux pour autres articles chirurgicaux
46.
Plasma-based films and methods for making and using the same
The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
A61L 15/40 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des ingrédients de constitution indéterminée ou leurs produits de réaction
A61L 31/00 - Matériaux pour autres articles chirurgicaux
The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.
The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.
The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.
The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterised in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.
The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.
The present invention relates to a method for the production of a recombinant target protein, in particular to a method comprising culturing a human host cell in a fortified cell culture medium. Embodiments of the invention were particularly developed for increasing the cell-specific productivity of host cells transfected with a nucleic acid sequence encoding human blood proteins such as coagulation Factor VIII (FVIII) and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
35 - Publicité; Affaires commerciales
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical products, namely blood coagulation factors, particularly recombinant factors VIII. Computer-software, especially on the basis of a mathematical model for prediction of the FVIII concentration in human plasma, especially after infusion of a dose of a blood coagulation factor, particularly based on a bayesian model to predict pharmaco kinetics. Medical and pharmaceutical information retrieval services; the aforementioned services both via hardcopy and/or internet. Providing information relating to medical and pharmaceutical services; the aforementioned services both via hardcopy and/or internet.
09 - Appareils et instruments scientifiques et électriques
35 - Publicité; Affaires commerciales
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Computer-software, especially on the basis of a mathematical model to predict pharmaco kinetics after infusion of a dose of medicines containing immunoglobulin. Medical and pharmaceutical information retrieval services; the aforementioned services both via hardcopy and/or internet. Providing information relating to medical and pharmaceutical services; the aforementioned services both via hardcopy and/or internet.
60.
HIGH CONCENTRATION IMMUNOGLOBULIN COMPOSITION FOR PHARMACEUTICAL APPLICATION
The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations, particularly blood plasma
preparations, plasma derivatives, coagulation factors,
growth factors, proteins derived from plasma. Treatment of materials, namely treatment of blood or blood
plasma in pharmaceutical preparations, particularly of blood
plasma preparations, plasma derivatives, coagulation
factors, growth factors, proteins derived from plasma. Medical services, particularly the medical services of a
blood donation center.
The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Treatment of materials, namely, treatment of blood or blood plasma in pharmaceutical preparations, particularly of blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma Pharmaceutical preparations, particularly blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma Medical services, particularly the medical services of a blood donation center
The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.
C12P 21/00 - Préparation de peptides ou de protéines
C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
B01D 15/08 - Adsorption sélective, p. ex. chromatographie
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations, particularly blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma. Treatment of materials, namely treatment of blood or blood plasma in pharmaceutical preparations, particularly of blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma. Medical services, particularly the medical services of a blood donation center.
79.
Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.
The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Training people with blood clotting disorders and their
relatives for the treatment of the illness in private life,
in particular for self-injection of blood coagulation
factors or for administration of drugs for the treatment of
blood coagulation disorders. Medical advice to patients with blood clotting disorders.
(1) Sterile, single use, disposable, needleless medical device for the reconstitution and transfer of drugs for intravenous application for the treatment of acute or traumatic bleeding episodes in patients with fibrinogen deficiency
Medical apparatus and instruments for reconstituting lyophilized fibrinogen powder; medical devices for transferring water to lyophilized fibrinogen powder to reconstitute the fibrinogen for preparation of fibrinogen solutions for injections and infusions
96.
PREPARATION COMPRISING FACTOR VIII AND VON WILLEBRAND FACTOR PEPTIDES
A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A process for manufacturing of a Factor VIII product having a ratio of FVIII :C/FVIII :Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; • An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. • An anionic chromatography resin. • A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98 % for treatment of haemophilia and avoiding formation of inhibitors.
